Answers are grounded in this paper and cite their sources.
The marketing authorization of Glybera and Strimvelis by the European Medicines Agency (EMA) marked the end of the long and often troubled road of gene therapy from biological concept to medical practice. Glybera is a recombinant adeno-associated virus (AAV) vector designed for gene therapy of lipoprotein lipase deficiency,1 while Strimvelis is a genetically modified hematopoietic stem cell preparation for the treatment of severe combined immunodeficiency.2 The US Food and Drug Administration (FDA) recently filled the gap for the US market by approving in rapid succession Ymlygic, a genetically modified oncolytic herpes virus, Kymriah and Yeskarta, two forms of genetically manipulated autologous T cells for immunotherapy of cancer, and Luxturna, a recombinant AAV vector for gene therapy of a rare form of retinal dystrophy.
No takes yet. Share an insight, caveat, or question.
Conlon et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: